ARO-APOC3
- Generic Name
- ARO-APOC3
- Drug Type
- Biotech
- Background
ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Phase 1
Completed
- Conditions
- HypertriglyceridemiaFamilial Chylomicronemia
- Interventions
- Drug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03783377
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath